TY - JOUR
T1 - Circulating soluble receptor for advanced glycation end product identifies patients with bicuspid aortic valve and associated aortopathies
AU - Branchetti, Emanuela
AU - Bavaria, Joseph E.
AU - Grau, Juan B.
AU - Shaw, Richard E.
AU - Poggio, Paolo
AU - Lai, Eric K.
AU - Desai, Nimesh D.
AU - Gorman, Joseph H.
AU - Gorman, Robert C.
AU - Ferrari, Giovanni
PY - 2014
Y1 - 2014
N2 - Objective - A total of 30% to 50% of patients with bicuspid aortic valve (BAV) require surgery for aortic valve replacement (AVR), ascending aortic replacement (AA), or both. To prevent adverse aortic events, they are risk stratified using imperfect criteria based on imaging modalities. As a result, a significant number of dissections occur outside of the parameters suggested by the guidelines. Advanced glycation end products (AGEs) are associated with valve and vascular remodeling and trigger the release of a soluble receptor (soluble receptor for advanced glycation end product [sRAGE]). This study aims to characterize sRAGE as a diagnostic and risk-stratification tool for patients with BAV referred for surgery.Approach and Results - sRAGE was measured in 135 patients (BAV, n=74; tricuspid aortic valve, n=61) meeting inclusion criteria from 338 enrolled patients undergoing AVR and AA. Univariate and multivariate analyses were performed. sRAGE level was significantly associated with the presence of BAV, independent of age, sex, and common risk factors for vascular disease (P2=0.007; P=0.51) or diameter/body surface area (R2=0.011; P=0.42).Conclusions - These results show that elevated level of circulating sRAGE is associated with the presence of BAV and associated aortopathies, independent of aortic diameter.
AB - Objective - A total of 30% to 50% of patients with bicuspid aortic valve (BAV) require surgery for aortic valve replacement (AVR), ascending aortic replacement (AA), or both. To prevent adverse aortic events, they are risk stratified using imperfect criteria based on imaging modalities. As a result, a significant number of dissections occur outside of the parameters suggested by the guidelines. Advanced glycation end products (AGEs) are associated with valve and vascular remodeling and trigger the release of a soluble receptor (soluble receptor for advanced glycation end product [sRAGE]). This study aims to characterize sRAGE as a diagnostic and risk-stratification tool for patients with BAV referred for surgery.Approach and Results - sRAGE was measured in 135 patients (BAV, n=74; tricuspid aortic valve, n=61) meeting inclusion criteria from 338 enrolled patients undergoing AVR and AA. Univariate and multivariate analyses were performed. sRAGE level was significantly associated with the presence of BAV, independent of age, sex, and common risk factors for vascular disease (P2=0.007; P=0.51) or diameter/body surface area (R2=0.011; P=0.42).Conclusions - These results show that elevated level of circulating sRAGE is associated with the presence of BAV and associated aortopathies, independent of aortic diameter.
KW - Advanced glyosylation end-product receptor
KW - Aortic aneurysm, thoracic
KW - Bicuspid aortic valve
UR - http://www.scopus.com/inward/record.url?scp=84914170429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84914170429&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.114.303784
DO - 10.1161/ATVBAHA.114.303784
M3 - Article
C2 - 25231638
AN - SCOPUS:84914170429
VL - 34
SP - 2349
EP - 2357
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
SN - 1079-5642
IS - 10
ER -